Key Facts: PRKCQ Domains and Mutations
PRKCQ (Protein Kinase C theta) belongs to the novel PKC subfamily. It contains three key functional domains: C2 domain, Protein kinase domain, and AGC-kinase C-terminal domain (UniProt Q04759). Known mutations include a somatic mutation found in a colorectal adenocarcinoma sample (VAR_042319), and two SNPs: rs45590231 and rs2236379 (UniProt Q04759). These mutations are relevant for drug resistance and patient stratification.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRKCQ drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRKCQ Kinase Domain (360-707aa) / Full-length Active Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. ATP-binding site integrity maintained. |
View PRKCQ Products |
| Gene Delivery | PRKCQ Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in T-cell lines (Jurkat/Primary). |
View PRKCQ Products |
| Benchmark Ab | Anti-PRKCQ (Phospho-Thr538 Specific) Recombinant rabbit monoclonal for target engagement validation. |
View PRKCQ Products |
| Validator | PRKCQ siRNA Set For knockdown verification in T-cell activation assays. |
View PRKCQ Products |
| PRKCA (PKCα) | Crucial for selectivity counter-screening against off-target toxicity. | View PRKCA Products |
| PRKCD (PKCδ) | Critical off-target within nPKC subfamily; required for kinase selectivity profiling. | View PRKCD Products |
| PRKCE (PKCε) | Novel PKC isoform for subfamily selectivity counter-screening. | View PRKCE Products |
| CARD11 | CBM Complex Scaffold Partner; upstream signaling node; essential for TCR-induced NF-κB pathway studies. | View CARD11 Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (vs PKCα, β, δ, ε, η) | Human PRKCQ + Ortholog Panel (Mouse/Rat/Cyno) with >95% purity; ATP-binding site sequence verified for accurate competition assays. |
| Drug Resistance Mutations | Mutant Recombinant Proteins (ATP-binding site variants); Theoretical MW confirmed; for resistance mechanism screening. |
| Cell-Based Target Engagement | Lentivirus for Stable Cell Line (HEK293/T-cell); High titer (>10^8 TU/ml); Endotoxin controlled. |
| Specificity Verification | Validated siRNA included for knockdown confirmation; Eliminates false positives in compound screening. |
Live PRKCQ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRKCQ (PKCθ) therapeutics is evolving rapidly, particularly in T-cell mediated autoimmune diseases and specific malignancies. Early non-selective PKC inhibitors faced significant safety hurdles due to off-target cardiovascular and metabolic toxicities. Current R&D is heavily focused on highly selective small molecules, allosteric inhibitors, and emerging targeted protein degradation (PROTAC) strategies. Major pharmaceutical players such as Merck (MSD), Biogen, and Bristol-Myers Squibb have advanced ATP-competitive inhibitors into Phase II trials for indications including rheumatoid arthritis and psoriasis. The next wave of development targets combination strategies with immune checkpoint inhibitors in solid tumors and precision medicine approaches in T-cell lymphomas. Known somatic mutations (e.g., in colorectal adenocarcinoma) and SNPs (rs45590231, rs2236379) underscore the importance of resistance mutation management. Future trends include isoform selectivity optimization (especially vs PKCδ and PKCε), CNS penetration for multiple sclerosis, and biomarker-driven patient stratification.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive) | Merck (MSD), Biogen, Bristol-Myers Squibb | Rheumatoid Arthritis, Psoriasis | Isoform Selectivity Panel (Need PRKCQ vs PRKCD/PRKCE proteins) |
| Small Molecule (Allosteric) | Preclinical Biotechs | Multiple Sclerosis | Conformational State Assay (Need Active vs Inactive PRKCQ mutants) |
| PROTAC/Degrader | Emerging Academic/Industry | T-cell Lymphoma | Cellular Knockdown Validation (Need siRNA controls) |
| Combination (IO) | Oncology Focused Biotechs | Solid Tumors (with PD-1) | T-cell Signaling Assay (Need Lentivirus for stable reporter lines) |